194 related articles for article (PubMed ID: 16623554)
1. Design and synthesis of potent cystine-free cyclic hexapeptide agonists at the human urotensin receptor.
Foister S; Taylor LL; Feng JJ; Chen WL; Lin A; Cheng FC; Smith AB; Hirschmann R
Org Lett; 2006 Apr; 8(9):1799-802. PubMed ID: 16623554
[TBL] [Abstract][Full Text] [Related]
2. Photolabelling the urotensin II receptor reveals distinct agonist- and partial-agonist-binding sites.
Holleran BJ; Beaulieu ME; Proulx CD; Lavigne P; Escher E; Leduc R
Biochem J; 2007 Feb; 402(1):51-61. PubMed ID: 17064254
[TBL] [Abstract][Full Text] [Related]
3. Identification of new agonists of urotensin-II from a cyclic peptide library.
Odagami T; Tsuda Y; Kogami Y; Kouji H; Okada Y
Bioorg Med Chem; 2009 Sep; 17(18):6742-7. PubMed ID: 19695883
[TBL] [Abstract][Full Text] [Related]
4. Urotensin-II receptor peptide agonists.
Carotenuto A; Grieco P; Novellino E; Rovero P
Med Res Rev; 2004 Sep; 24(5):577-88. PubMed ID: 15224381
[TBL] [Abstract][Full Text] [Related]
5. Three-dimensional model of the human urotensin-II receptor: docking of human urotensin-II and nonpeptide antagonists in the binding site and comparison with an antagonist pharmacophore model.
Lescot E; Sopkova-de Oliveira Santos J; Colloc'h N; Rodrigo J; Milazzo-Segalas I; Bureau R; Rault S
Proteins; 2008 Oct; 73(1):173-84. PubMed ID: 18409194
[TBL] [Abstract][Full Text] [Related]
6. Architecture of the human urotensin II receptor: comparison of the binding domains of peptide and non-peptide urotensin II agonists.
Lavecchia A; Cosconati S; Novellino E
J Med Chem; 2005 Apr; 48(7):2480-92. PubMed ID: 15801838
[TBL] [Abstract][Full Text] [Related]
7. Unraveling the active conformation of urotensin II.
Carotenuto A; Grieco P; Campiglia P; Novellino E; Rovero P
J Med Chem; 2004 Mar; 47(7):1652-61. PubMed ID: 15027856
[TBL] [Abstract][Full Text] [Related]
8. New insight into the binding mode of peptide ligands at Urotensin-II receptor: structure-activity relationships study on P5U and urantide.
Grieco P; Carotenuto A; Campiglia P; Gomez-Monterrey I; Auriemma L; Sala M; Marcozzi C; d'Emmanuele di Villa Bianca R; Brancaccio D; Rovero P; Santicioli P; Meini S; Maggi CA; Novellino E
J Med Chem; 2009 Jul; 52(13):3927-40. PubMed ID: 19432421
[TBL] [Abstract][Full Text] [Related]
9. Urotensin-II receptor ligands. From agonist to antagonist activity.
Grieco P; Carotenuto A; Campiglia P; Marinelli L; Lama T; Patacchini R; Santicioli P; Maggi CA; Rovero P; Novellino E
J Med Chem; 2005 Nov; 48(23):7290-7. PubMed ID: 16279788
[TBL] [Abstract][Full Text] [Related]
10. Structure-activity relationship study on human urotensin II.
Guerrini R; Camarda V; Marzola E; Arduin M; Calo G; Spagnol M; Rizzi A; Salvadori S; Regoli D
J Pept Sci; 2005 Feb; 11(2):85-90. PubMed ID: 15635628
[TBL] [Abstract][Full Text] [Related]
11. Nonpeptide Urotensin-II receptor agonists and antagonists: review and structure-activity relationships.
Lescot E; Bureau R; Rault S
Peptides; 2008 May; 29(5):680-90. PubMed ID: 18022732
[TBL] [Abstract][Full Text] [Related]
12. Synthesis of potent cyclic hexapeptide NK-1 antagonists. Use of a minilibrary in transforming a peptidal somatostatin receptor ligand into an NK-1 receptor ligand via a polyvalent peptidomimetic.
Hirschmann R; Yao W; Cascieri MA; Strader CD; Maechler L; Cichy-Knight MA; Hynes J; van Rijn RD; Sprengeler PA; Smith AB
J Med Chem; 1996 Jun; 39(13):2441-8. PubMed ID: 8691440
[TBL] [Abstract][Full Text] [Related]
13. Photolabelling the rat urotensin II/GPR14 receptor identifies a ligand-binding site in the fourth transmembrane domain.
Boucard AA; Sauvé SS; Guillemette G; Escher E; Leduc R
Biochem J; 2003 Mar; 370(Pt 3):829-38. PubMed ID: 12495432
[TBL] [Abstract][Full Text] [Related]
14. Functional and binding characterizations of urotensin II-related peptides in human and rat urotensin II-receptor assay.
Brkovic A; Hattenberger A; Kostenis E; Klabunde T; Flohr S; Kurz M; Bourgault S; Fournier A
J Pharmacol Exp Ther; 2003 Sep; 306(3):1200-9. PubMed ID: 12807997
[TBL] [Abstract][Full Text] [Related]
15. Biological properties and functional determinants of the urotensin II receptor.
Proulx CD; Holleran BJ; Lavigne P; Escher E; Guillemette G; Leduc R
Peptides; 2008 May; 29(5):691-9. PubMed ID: 18155322
[TBL] [Abstract][Full Text] [Related]
16. Structure-activity relationship study of position 4 in the urotensin-II receptor ligand U-II(4-11).
Marzola E; Camarda V; Batuwangala M; Lambert DG; Calo' G; Guerrini R; Trapella C; Regoli D; Tomatis R; Salvadori S
Peptides; 2008 May; 29(5):674-9. PubMed ID: 17822806
[TBL] [Abstract][Full Text] [Related]
17. Urotensin-II receptor modulators as potential drugs.
Maryanoff BE; Kinney WA
J Med Chem; 2010 Apr; 53(7):2695-708. PubMed ID: 20043680
[No Abstract] [Full Text] [Related]
18. Lead optimization of P5U and urantide: discovery of novel potent ligands at the urotensin-II receptor.
Carotenuto A; Auriemma L; Merlino F; Yousif AM; Marasco D; Limatola A; Campiglia P; Gomez-Monterrey I; Santicioli P; Meini S; Maggi CA; Novellino E; Grieco P
J Med Chem; 2014 Jul; 57(14):5965-74. PubMed ID: 24992374
[TBL] [Abstract][Full Text] [Related]
19. Novel and potent small-molecule urotensin II receptor agonists.
Lehmann F; Currier EA; Clemons B; Hansen LK; Olsson R; Hacksell U; Luthman K
Bioorg Med Chem; 2009 Jul; 17(13):4657-65. PubMed ID: 19481466
[TBL] [Abstract][Full Text] [Related]
20. Alkylated sugar amino acids: a new entry toward highly functionalized dipeptide isosters.
Raunkjaer M; El Oualid F; van der Marel GA; Overkleeft HS; Overhand M
Org Lett; 2004 Sep; 6(18):3167-70. PubMed ID: 15330614
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
